Matwings Technology Secures Major Funding for Protein Innovation

Matwings Technology Secures Significant Series A Funding

'Beyond Structure, Predicting Function'

Recently, Shanghai Matwings Technology Co., Ltd. ('Matwings'), a global leader in AI-driven protein design, announced the successful completion of its funding rounds, raising tens of millions of USD. The investment was led by Qiming Venture Partners.

Matwings is redefining the field of protein engineering with its innovative AI-based protein design platform, AccelProtein™, which is capable of predicting protein functionality that goes beyond just structural attributes. This leap forward facilitates a new pathway for attaining highly functional proteins that can serve diverse applications.

At the heart of AccelProtein™ is the Pro-PRIME model, a groundbreaking advancement developed by a collaborative team spearheaded by Professor Liang Hong at Shanghai Jiao Tong University. Following years of meticulous research encompassing data collection, curation, and optimization, the team unveiled the Pro-series, an AI framework dedicated to protein design. Their significant findings were recently showcased in a publication in Science Advances.

A notable highlight of AccelProtein™ is its role in designing a specialized Glycosyltransferase enzyme, utilized in producing EPS-G7, pivotal for pancreatitis screening. Within a mere four months, this project resulted in a sevenfold increase in the enzyme's total glycosylation activity, while also enhancing product specificity from 60% to an impressive 98%, and reducing hydrolytic activity by one-third. These advancements have led to a remarkable 90% reduction in the overall costs related to EPS-G7 production.

Another exciting development involved Matwings engineering a super alkali-resistant affinity ligand, known as a nanobody, for affinity chromatography applications. This innovation improved alkali resistance threefold, doubled binding capacity, and increased heat stability significantly. Such improvements have resulted in substantial cost savings for clients in the chemistry and manufacturing control (CMC) domain. Moreover, scaling up production to 5000L has already been accomplished, enabling affordable affinity chromatography purification for various biologics.

Since its inception in 2021, Matwings has successfully executed over 30 projects focused on protein engineering and enzyme mining. These projects, which include proprietary enzymes like Enterokinase, Carboxypeptidase B, and others, illustrate Matwings' capabilities across diverse sectors such as drug development, in vitro diagnostics, nutrition and healthcare, food and beverage, and renewable energy.

About Matwings

Founded in 2021 by a distinguished team from Shanghai Jiao Tong University, Matwings has rapidly emerged as a frontrunner in AI protein modeling.

The company is committed to transcending traditional directed evolution techniques, utilizing a sophisticated, proprietary AI platform that boasts a database of 780 million curated full-length protein sequences, including nearly 500 million unique private data.

This state-of-the-art technology platform, AccelProtein™, empowers Matwings to not only engineer proteins effectively but also facilitate the discovery of novel proteins with enhanced attributes such as stability, activity, affinity, and yield.

Currently, Matwings is engaged in more than 40 ongoing projects spanning various applications within both the pharmaceutical and synthetic biology industries. They are dedicated to developing essential enzymes and proteins necessary for sustainable bioprocessing, innovative biologics, synthetic biology applications, and more.

Actively pursuing global partnerships, Matwings aims to collaborate with industry leaders to co-develop and commercialize supporting products.

Contact Information:
Email: [email protected]
Website: https://www.matwings.com/en/
Tel: +86 158 2106 5410

Frequently Asked Questions

What is Matwings Technology known for?

Matwings Technology specializes in AI-driven protein design, developing advanced algorithms to enhance protein functionality and efficiency.

What recent funding did Matwings achieve?

Matwings successfully raised tens of millions of USD in Series A funding, led by Qiming Venture Partners.

How does AccelProtein™ work?

AccelProtein™ utilizes AI to predict protein functionality, allowing for the design and optimization of proteins with enhanced characteristics.

What industries does Matwings serve?

Matwings caters to various industries, including pharmaceuticals, healthcare, food and beverage, and renewable energy.

What advancements has Matwings made in protein engineering?

Matwings has developed innovative enzymes, including Glycosyltransferases, leading to increased efficiency and reduced production costs across multiple applications.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.